Zidovudine Articles
Initial therapy with Viracept may avoid emergence of HIV "superbugs"
24 December 2001
HIV/AIDS patients "must get drug treatment," says Mandela
3 December 2001
Chinese firms apply to make HIV/AIDS drugs
20 November 2001
Need for differentiated drug access policies
30 October 2001
TAC seeks to settle with S Africa govt
30 October 2001
Immune Response cancels Remune trial
3 September 2001
GSK sued for Retrovir death in Sth Africa
16 July 2001
Cipla drops HIV/AIDS cocktail price in India
13 July 2001
Superior efficacy for Ziagen/Combivir
11 July 2001
DuPont's Sustiva tops PI therapy over 3 years
10 July 2001
BI's tipranavir effective as HIV salvage regimen
10 July 2001
Cadila applies to make cheap HIV/AIDS drugs
3 July 2001
UK MRC to fund Viramune study
3 July 2001
Burundi signs up for UN HIV/AIDS drug plan
2 May 2001
Mali, Cameroon to get cheap HIV/AIDS drugs
11 April 2001
GSK: "Combivir's price goes no lower"
9 April 2001
GSK "surprise" at SA HIV/AIDS drugs claim
23 February 2001
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
Cipla talks with MNCs over HIV drug offer
13 February 2001
Earnings increase 41% at BioChem Pharma
1 February 2001
S Africa nevirapine trial in HIV mothers
31 January 2001
GSK's Trizivir cleared in EU for HIV
9 January 2001
Warnings issued on use of B-MS' antiretrovirals in pregnancy
8 January 2001
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
S Africa OKs generic Diflucan imports
1 December 2000
Cipla suspends HIV drug exports to Ghana
16 November 2000
GW wins FDA approval for Trizivir
16 November 2000
Antiretrovirals backed by WHO for HIV MTCT
10 November 2000
South African AIDS guide drugs row
26 October 2000
Gilead Sciences boosted on tenefovir DF resistance data
25 October 2000
HIV/AIDS therapy sales forecasts to 2009
3 August 2000
Triangle's DAPD shows promise in resistant HIV
20 July 2000
GW's anti-HIV drug Trizivir backed in EU
18 July 2000
BI offers free Viramune to developing countries
7 July 2000
Thailand boosts locally- made HIV generics
30 June 2000
BioChem Pharma earnings up 34%
3 May 2000
BI's Viramune shows efficacy in advanced HIV
3 February 2000
First clinical data for Agouron's capravirine
2 February 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Thailand tests USA's new trade line on drugs
21 December 1999
GW seeks backing for Trizivir, new HIV combo
20 December 1999
BioChem Pharma profits up 17%
29 October 1999
Sustiva, Combivir "beat HIV non-compliance"
13 October 1999
New generation of anti-HIV drugs unveiled at ICAAC
13 October 1999
Remune combo trial
27 September 1999
Sharp earnings rise at BioChem Pharma
2 August 1999
GW gains EU approval for Ziagen
13 July 1999
BioChem Pharma posts 39% revenue rise
5 May 1999
South Africa tells AIDS drugmakers:cut your prices
30 April 1999
French tribunal ruling hits generics moves
12 April 1999
BioChem Pharma starts Phase II troxacitabine
8 April 1999
Sustiva cleared in Canada for HIV
29 March 1999
Sustiva-based HIV therapy assessed
18 February 1999
US HIV conference data in brief
4 February 1999
Epivir boosts earnings at BioChem Pharma
3 February 1999
Low compliance could fuel AIDS epidemic
26 January 1999
G-W's Ziagen approved in USA
21 December 1998
Canada Approve Combivir for HIV Infection
9 December 1998
GW's Ziagen Endorsed By FDA Committee
3 November 1998
First Filings For GW's Amprenavir
20 October 1998
Date Set For Ziagen Review In USA
8 October 1998
First Phase III Data With GW's Agenerase
1 October 1998
First Approval Of DuPont's Sustiva In USA
21 September 1998
FDA Approves Isis And CIBA Vision's Vitravene
1 September 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
Healthy 2nd Qtr Sales/ Earnings At BioChem
5 August 1998
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
